Acorda Therapeutics, Inc. (ACOR) Social Stream

Featured Post From StockTwits About ACOR

$ACOR Few insights from the quarterly report: and please read it. I did. Inbrija and Amprya both are doing extremely well, even with the unusual conditions and the new variant.
More than enough liquidity for the coming years, that is not really needed…
But the most important is the hints with regard to the Ex, U.S sales on other parts of Europe and Japan. They are also discussing collaboration and other candidates for the Arcus technology. Management has the experience, the time to make the best commercial aggressive on Inbrija and they will do it only when it is best for the company. Just before those announcements will be out the stock is going to fly…and when they are published and executed the market value is going to reflect the numbers… If they committed to 18 millions on Inbrija from Catalent - every year until 2030 they know something with regard to actual sales…I’m all in!